


# Resistance Trends of *Klebsiella pneumoniae* Causing Urinary Tract Infections in Chongqing, 2011–2019

This article was published in the following Dove Press journal:  
*Infection and Drug Resistance*

Yanhui Ding  
Huijuan Wang  
Shuli Pu  
Shifeng Huang <sup>\*</sup>  
Siqiang Niu <sup>\*</sup>

Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China

\*These authors contributed equally to this work

**Purpose:** To analyze the characteristics and trends of drug resistance for *Klebsiella pneumoniae* (*K. pneumoniae*), isolated from urinary tract infections (UTIs), to common antibiotics used in clinics.

**Methods:** This retrospective study was conducted in a teaching hospital in Chongqing from 2011 to 2019. Laboratory data of isolated bacteria were collected and analyzed.

**Results:** Among the 17,966 non-repetitive strains isolated from the urine sample, a total of 1543 *K. pneumoniae* isolates were identified, with an isolation frequency secondary only to *Escherichia coli* (*E. coli*) and there was a peak in the *K. pneumoniae* isolates in the year 2013. During the period, the rate of extended-spectrum  $\beta$ -lactamase (ESBL)-producing *K. pneumoniae* fell from 48.4% in 2011 to 32.9% in 2019, and a marked jump of resistance was seen in carbapenems from 2.2% to 18.0%. The peak of carbapenem resistance rate (22.6%) to *K. pneumoniae* was observed in 2017 along with a low ESBL-producing rate (30.9%). Piperacillin/tazobactam and cefepime resistance levels went up from 4.4% to 25.7% and from 18.2% to 30.5%, respectively. Moreover, the *K. pneumoniae* isolates resistance rate to carbapenems and amikacin gradually grew up, showing their peaks in 2017, and then dropped year by year. However, ceftazidime and aztreonam resistance levels were relatively stable, fluctuating between 21.8% and 35.6%, 32.2% and 39.4%, respectively.

**Conclusion:** There is a significant upward tendency in carbapenem resistance rate and a downward tendency in ESBL-production rate in *K. pneumoniae* isolates from UTIs, and continuous surveillance is necessary in the future.

**Keywords:** urinary tract infections, *Klebsiella pneumoniae*, carbapenem resistance, extended-spectrum  $\beta$ -lactamase

## Introduction

Urinary tract infections (UTIs) are the most frequent bacterial infection in primary care, affecting 150 million people per year worldwide.<sup>1</sup> UTI is an inflammatory reaction caused by the invasion of pathogenic microorganisms in the urinary tract, which is a common infection among the inpatients in recent years, and the inappropriate use and abuse of broad-spectrum antibiotics for decolonization not only results in a decrease in the effectiveness of standard treatments, but also leads to the emergence of multidrug resistance.<sup>2,3</sup> A modelling study showed that about 3 million severe infections were caused by carbapenem-resistant *Escherichia coli* (*E. coli*) and *Klebsiella pneumoniae* (*K. pneumoniae*) worldwide.<sup>4</sup>

Accelerated emergence and effective propagation of carbapenem-resistant *K. pneumoniae* (CR-KPN) across the world have become a prominent public health challenge due to high mortality rate in healthcare-associated nosocomial

Correspondence: Siqiang Niu;  
Shifeng Huang  
Email siqiangniu@cqmu.edu.cn;  
sfhuang@hospital.cqmu.edu.cn

infections.<sup>5,6</sup> Approximately 60%-80% of UTIs are caused by *E. coli* and 3%-10% by *K. pneumoniae*.<sup>7-9</sup> This last is an important pathogen that causes a wide range of infections such as pneumonia and bloodstream infections, commonly in neonates and patients admitted in intensive care units. Carbapenems is the last defense against extended-spectrum  $\beta$ -lactamase (ESBL)-producing *K. pneumoniae* and their frequent use has resulted in the generation and spread of CR-KPN, a clinically significant carbapenem-resistant *Enterobacteriales* (CRE).<sup>10</sup> Since outbreak of CR-KPN in New York hospitals in the early 2000s, this pathogen has spread throughout the United States and worldwide.<sup>11,12</sup> In China, CR-KPN infections prevailed from 2.9% in 2005 to 40% in 2017 and the distribution differed greatly by region, with the lowest in northeast and the highest in eastern region of China.<sup>13-15</sup> Here, we investigated the distribution and drug resistance trends of *K. pneumoniae* causing UTIs in a tertiary teaching hospital from 2011 to 2019 to provide reference for rational use of antibiotics.

## Materials and Methods

### Data Collection

This retrospective study data were collected in the microbiology laboratory of the First Affiliated Hospital of Chongqing Medical University using WHONET software. Strains were isolated from various patients' urine culture routinely according to the hospital laboratory procedure, and only the first isolate was included in our study. Duplicate isolates, defined as the same bacterial species from the same inpatient during the same inpatient stay, were excluded from analysis.

### Antimicrobial Susceptibility Testing

A total of 1543 *K. pneumoniae* isolates recovered from urine were correctly identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (bioMérieux, MO, France), assisted with Vitek-2 compact system (bioMérieux, MO, France) according to the manufacturer's instructions. All the isolates were sub-cultured on blood agar and MacConkey agar plates for purity check to confirm species. The susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) criteria using the automated Vitek-2 compact system, and further on Mueller Hinton's agar by the Kirby-Bauer Disk Diffusion method for the following antimicrobials: aztreonam

(30 $\mu$ g), meropenem (10 $\mu$ g), ciprofloxacin (5 $\mu$ g) and gentamicin (30 $\mu$ g). The ESBL test was identified by clavulanic acid synergy test, which is included in the AST-GN334 card (bioMérieux, Marcy l'Etoile, France).<sup>16</sup> Isolates were defined as CR-KPN if they were resistant to any one of carbapenems tested. MIC results were interpreted according to the CLSI guidelines.<sup>17</sup> Quality control was performed with each run using the strains *Enterobacter hormaechei* ATCC 700323 and *Escherichia coli* ATCC 25922, to ensure reproducibility of the antibiotic susceptibility testing procedure.

## Results

### Distribution of Strains

A total of 17,966 strains were isolated from urine culture during the 9 years of study period in our hospital in Chongqing, Southwest China. The top five species among the total identified isolates were *E. coli*, *K. pneumoniae*, *Enterococcus faecium*, *Enterococcus faecalis* and *Pseudomonas aeruginosa*. The annual isolation number of *K. pneumoniae* ranged from 91 to 205 during the 9 years, with 91 (7.9%) strains in the year 2011, 137 (6.7%) in 2012, 205 (9.2%) in 2013, 189 (8.4%) in 2014, 203 (8.6%) in 2015, 177 (8.0%) in 2016, 191 (9.3%) in 2017, 182 (9.6%) in 2018, and 167 (9.5%) in 2019. There was a peak in the *K. pneumoniae* isolates in the year 2018, accounting for up to 9.6% of the total isolates (Figure 1). Of note, the vast majority of the strains were isolated from the hospitalized patients (data not shown).


### Characteristics of *K. pneumoniae*

Temporal trends and changes in both the rates of ESBL-production and carbapenem-resistance, and antimicrobial resistance levels in urinary *K. pneumoniae* isolates over the study period are presented in Figure 2 and Table 1. During this period, the rate of ESBL-producing *K. pneumoniae* reduced from 48.4% in 2011 to 32.9% in 2019, but a marked increase of resistance against carbapenems was seen from 2.2 to 18.0%. The peak of carbapenem resistance (22.6%) was observed in 2017 along with the low ESBL-production rate (30.9%) in *K. pneumoniae*. (Figure 2)

### Antibioresistance Profiles of


#### *K. pneumoniae*

Antimicrobial agents checked included quinolones (ciprofloxacin and levofloxacin), sulfonamides (cotrimoxazole),



**Figure 1** Distribution of strains isolated from urine for the 9-year study.

**Abbreviations:** *E. coli*, *Escherichia coli*; *K. pneumoniae*, *Klebsiella pneumoniae*; *P. aeruginosa*, *Pseudomonas aeruginosa*; *E. faecalis*, *Enterococcus faecalis*; *E. faecium*, *Enterococcus faecium*.



**Figure 2** Rates of ESBL-producing and Carbapenem resistant-*K. pneumoniae* from 2011 to 2019.

**Abbreviations:** CR-KPN, carbapenem resistant-*K. pneumoniae*; ESBL-KPN, ESBL-producing *K. pneumoniae*.

third-generation cephalosporins (ceftazidime and ceftriaxone), fourth-generation cephalosporins (cefepime), cephamycins (cefoxitin and cefotetan), other penicillins (piperacillin/tazobactam), carbapenems (ertapenem, imipenem and meropenem), aminoglycosides (gentamicin, amikacin and tobramycin) and monocyclic  $\beta$ -lactam antibiotics (aztreonam). With regard to drug susceptibility of *K. pneumoniae*, ESBL producers accounted from 48.4% in 2011 to 32.9% in 2019 (Figure 2). ESBL-producing *K. pneumoniae* showed a high resistance rate to the antibiotics except cefoxitin, cefotetan, piperacillin/tazobactam, amikacin and carbapenems, while CRKP was highly resistant to all antibiotics (Table 2).

Moreover, piperacillin/tazobactam and cefepime resistance levels increased from 4.4% to 25.7% and from 18.2% to 30.5%, respectively (Table 1). The resistance rate of carbapenems and amikacin gradually rose from 2011 to 2017, reaching its peaking in 2017, and then went down year by year. However, ceftazidime and aztreonam resistance levels were stable, fluctuating between 21.8% and 35.6%, 32.2% and 39.4%, respectively (Table 1).

## Discussion

Our study highlights the decreasing detection rate of ESBL-producing coupled with rising resistance rates of

**Table I** Resistance Rates (%) of Urine *K. pneumoniae* Isolates to Antimicrobial Agents

| Antibiotics | 2012    |      | 2013    |      | 2014    |      | 2015    |      | 2016    |      | 2017    |       | 2018    |       | 2019    |       |
|-------------|---------|------|---------|------|---------|------|---------|------|---------|------|---------|-------|---------|-------|---------|-------|
|             | n = 137 |      | n = 205 |      | n = 189 |      | n = 203 |      | n = 177 |      | n = 191 |       | n = 182 |       | n = 167 |       |
|             | n       | R%   | n       | R%   | n       | R%   | n       | R%   | n       | R%   | n       | R%    | n       | R%    | n       | R%    |
| <b>SAM</b>  | 137     | 62.0 | 205     | 56.1 | 183     | 59.0 | 188     | 49.5 | 172     | 55.8 | 188     | 60.6  | 182     | 50.5  | /       | /     |
| <b>TZP</b>  | 137     | 4.4  | 205     | 1.5  | 183     | 2.2  | 188     | 5.9  | 172     | 11.6 | 188     | 23.4  | 182     | 13.7  | 167     | 25.7  |
| <b>CAZ</b>  | 137     | 31.4 | 205     | 28.8 | 183     | 26.8 | 188     | 21.8 | 172     | 27.3 | 188     | 35.6  | 182     | 28.0  | 167     | 29.3  |
| <b>CRO</b>  | 137     | 56.9 | 205     | 56.6 | 183     | 53.0 | 188     | 43.1 | 172     | 43.6 | 190     | 53.7  | 182     | 45.6  | 167     | 46.7  |
| <b>FEP</b>  | 137     | 18.2 | 205     | 17.6 | 183     | 15.3 | 188     | 11.2 | 172     | 19.2 | 188     | 30.9  | 182     | 22.0  | 167     | 30.5  |
| <b>CTT</b>  | 137     | 2.9  | 205     | 0.5  | 183     | 2.7  | 188     | 4.3  | 172     | 11.0 | 188     | 19.1  | 182     | 15.4  | /       | /     |
| <b>FOX</b>  | /       | /    | /       | /    | /       | /    | 155     | 13.5 | 158     | 24.7 | 180     | 28.9  | 181     | 28.7  | 136     | 28.7  |
| <b>ATM</b>  | 137     | 35.8 | 205     | 36.6 | 183     | 36.6 | 188     | 32.4 | 172     | 32.6 | 188     | 39.4  | 180     | 32.2  | 145     | 34.5* |
| <b>ETP</b>  | 133     | 6.0  | 200     | 2.0  | 182     | 3.3  | 182     | 4.4  | 171     | 9.9  | 190     | 22.6  | 182     | 17.0  | 167     | 16.8  |
| <b>IPM</b>  | 137     | 1.5  | 205     | 0    | 183     | 0.5  | 188     | 4.3  | 172     | 8.7  | 190     | 20.0  | 182     | 13.7  | 167     | 11.4  |
| <b>MEM</b>  | /       | /    | /       | /    | /       | /    | 163     | 4.3* | 159     | 8.2* | 184     | 18.5* | 181     | 13.8* | 153     | 11.1* |
| <b>AMK</b>  | 137     | 7.3  | 205     | 6.8  | 175     | 6.3  | 175     | 6.9  | 164     | 10.4 | 181     | 21.5  | 182     | 15.4  | 167     | 10.8  |
| <b>GEN</b>  | 137     | 42.3 | 205     | 51.7 | 183     | 41.5 | 188     | 33.5 | 175     | 38.3 | 190     | 45.8  | 182     | 34.1  | 51      | 23.5  |
| <b>TOB</b>  | 137     | 14.6 | 204     | 21.1 | 183     | 22.4 | 188     | 14.9 | 172     | 16.9 | 188     | 33.0  | 182     | 19.8  | /       | /     |
| <b>CIP</b>  | 137     | 55.5 | 205     | 51.2 | 183     | 59.0 | 188     | 48.9 | 172     | 54.1 | 188     | 58.5  | 182     | 52.2  | /       | /     |
| <b>LVX</b>  | 137     | 38.0 | 205     | 35.6 | 183     | 41.0 | 188     | 37.8 | 172     | 39.0 | 188     | 38.3  | 182     | 40.1  | 167     | 36.5  |
| <b>SXT</b>  | 50      | 54.0 | 205     | 53.2 | 183     | 60.1 | 187     | 46.0 | 172     | 54.7 | 188     | 50.5  | 181     | 41.4  | 167     | 43.1  |

**Notes:** \*The data are results using Kirby-Bauer method; /, the data are not detected.

**Abbreviations:** SAM, ampicillin/sulbactam; TZP, piperacillin/tazobactam; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; CTT, cefotetan; FOX, ceftiofur; ATM, aztreonam; ETP, ertapenem; IPM, imipenem; MEM, meropenem; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; LVX, levofloxacin; SXT, sulfamethoxazole/trimethoprim.

*K. pneumoniae* to carbapenems. Isolates of *K. pneumoniae* are becoming increasingly resistant to antibiotics and subsequently may become even more difficult to be treated.<sup>18</sup> Overall, we found a significant reduction of ESBL detection rate for the *K. pneumoniae* in UTIs from 2011 to 2019. Fortunately, from 2011 onwards, there is a requirement for all hospitals in China to form an antibiotic administrative group with the aim to enforce formulary restrictions and total inpatient consumption of antibiotics (>40 defined daily doses/100 inpatient days).<sup>19</sup> The outbreaks of CR-KPN have become increasingly common in China,<sup>20,21</sup> and we found a growing prevalence of CR-KPN in the UTIs through retrospective analysis, consistent with findings from previous large surveillance studies.<sup>13</sup>

We found that the detection of CR-KPN isolates from UTI patients reached its peak in 2017, accompanied by the high resistance rates to carbapenems and amikacin. While piperacillin/tazobactam and cefepime resistance levels increased year after year, ceftazidime and aztreonam resistance levels were relatively stable. Of note, CR-KPN was almost resistant to all the antibiotics tested. High rates of bacterial resistance are often correlated with high rates of

antibiotic use and intra- and inter-hospital spread of antibiotic-resistant bacteria.<sup>22</sup> In addition, increasing consumption of  $\beta$ -lactam/ $\beta$ -lactamase inhibitors may also increase the frequency of carbapenem-resistant *Klebsiella* spp.<sup>23–25</sup>

*K. pneumoniae* can cause serious, life-threatening infections in humans in endemic and epidemic settings.<sup>26</sup> Resistance to carbapenems in *Enterobacteriales* is primarily linked to different mechanisms, in particular the production of carbapenemases.<sup>10</sup> Carbapenems are the main defense against ESBL-producing pathogens, the overuse of which has resulted in the generation and spread of CR-KPN, which is a clinically significant CRE. A series of molecular epidemiology studies on CRE in China have shown that the outbreaks caused by KPC-2-producing *K. pneumoniae* in these regions were due to the spread of the predominant clone ST11, which is a variant of international clone ST258.<sup>26–30</sup> ST258 is strongly associated with KPC production and multidrug resistance, but it may have inherent traits which are responsible for its high rate of transmissibility that results from two distinct genetic clades with a hot spot for DNA recombination.<sup>31</sup>

**Table 2** Resistance Rates of Urine *K. pneumoniae* Isolates with Diverse Characteristics to Antimicrobial Agents

| Antibiotics | ESBL(+)-KPN    |                | ESBL(-)-KPN    |                | CR-KPN          |               | CSE-KPN         |                   |
|-------------|----------------|----------------|----------------|----------------|-----------------|---------------|-----------------|-------------------|
|             | R (%)          | S (%)          | R (%)          | S (%)          | R (%)           | S (%)         | R (%)           | S (%)             |
| SAM         | 85.3 (480/563) | 2.8 (16/563)   | 34.5 (268/777) | 60.6 (471/777) | 100.0 (122/122) | 0 (0/122)     | 50.8 (599/1180) | 40.6 (480/1180)   |
| TZP         | 6.6 (41/617)   | 83.6 (516/617) | 13.6 (120/884) | 82.4 (728/884) | 79.2 (118/149)  | 9.4 (14/149)  | 3.2 (42/1314)   | 91.2 (1198/1314)  |
| CAZ         | 43.6 (269/617) | 50.2 (310/617) | 18.3 (162/885) | 80.5 (712/885) | 96.6 (144/149)  | 3.4 (5/149)   | 20.5 (269/1314) | 75.9 (997/1314)   |
| CRO         | 95.8 (591/617) | 3.4 (21/617)   | 17.8 (158/886) | 81.6 (723/886) | 98.7 (147/149)  | 1.3 (2/149)   | 44.3 (583/1316) | 55.1 (725/1316)   |
| FEP         | 25.6 (158/617) | 70.5 (435/617) | 12.2 (108/885) | 86.9 (769/885) | 85.9 (128/149)  | 8.7 (13/149)  | 10.3 (135/1314) | 88.1 (1158/1314)  |
| CTT         | 1.8 (10/563)   | 96.4 (543/563) | 11.7 (91/777)  | 86.5 (672/777) | 76.2 (93/122)   | 14.8 (18/122) | 0.5 (6/1180)    | 98.6 (1163/1180)  |
| FOX         | 22.9 (64/279)  | 71.3 (199/279) | 25.8 (138/534) | 71.2 (380/534) | 99.1 (111/112)  | 0.9 (1/112)   | 12.8 (85/664)   | 82.8 (550/664)    |
| ATM         | 62.6 (382/610) | 35.7 (218/610) | 15.0 (131/872) | 84.5 (737/872) | 92.3 (132/143)  | 7.0 (10/143)  | 28.0 (364/1300) | 71.0 (923/1300)   |
| ETP         | 4.2 (26/615)   | 94.6 (582/615) | 13.5 (119/880) | 85.8 (755/880) | 100.0 (149/149) | 0 (0/149)     | 0 (0/1316)      | 100.0 (1316/1316) |
| IPM         | 0.6 (4/617)    | 98.9 (610/617) | 11.5 (102/886) | 88.0 (780/886) | 71.8 (107/149)  | 22.8 (34/149) | 0 (0/1316)      | 100.0 (1316/1316) |
| MEM         | 1.4 (4/287)    | 97.2 (279/287) | 16.2 (90/557)  | 83.5 (465/557) | 80.0 (92/115)   | 15.7 (18/115) | 0 (0/686)       | 100 (686/686)     |
| AMK         | 8.2 (49/597)   | 91.6 (547/597) | 12.2 (106/868) | 87.8 (762/868) | 66.9 (97/145)   | 33.1 (48/145) | 4.3 (55/1284)   | 95.6 (1228/1284)  |
| GEN         | 64.8 (378/583) | 34.1 (199/583) | 23.0 (190/826) | 76.3 (630/826) | 76.3 (100/131)  | 22.9 (30/131) | 36.5 (45/1235)  | 62.9 (777/1235)   |
| TOB         | 26.3 (148/563) | 29.3 (165/563) | 16.1 (125/777) | 71.9 (559/777) | 76.2 (93/122)   | 10.7 (13/122) | 14.6 (172/1180) | 58.8 (694/1180)   |
| CIP         | 51.1 (313/613) | 40.6 (249/613) | 27.5 (241/876) | 70.2 (615/876) | 91.7 (133/145)  | 6.9 (10/145)  | 30.7 (400/1305) | 64.2 (838/1305)   |
| LVX         | 38.9 (240/617) | 54.0 (333/617) | 24.1 (213/884) | 73.0 (645/884) | 87.2 (130/149)  | 11.4 (17/149) | 23.2 (305/1314) | 71.6 (941/1314)   |
| SXT         | 80.4 (456/567) | 19.6 (111/567) | 32.8 (277/846) | 67.2 (569/846) | 60.6 (87/143)   | 39.4 (56/143) | 51.0 (630/1236) | 49.0 (606/1236)   |

**Abbreviations:** ESBL(+)-KPN, ESBL-producing *K. pneumoniae*; ESBL(-)-KPN, non ESBL-producing *K. pneumoniae*; CR-KPN, carbapenem-resistant *K. pneumoniae*; CSE-KPN, carbapenem-sensitive *K. pneumoniae*; SAM, ampicillin/sulbactam; TZP, piperacillin/tazobactam; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; CTT, cefotetan; FOX, cefoxitin; ATM, aztreonam; ETP, eripenem; MEM, meropenem; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; LVX, levofloxacin; SXT, sulfamethoxazole/trimethoprim.



There are some limitations of this work. This study is retrospective in nature, so some potential confounders, such as the length of stay, patients from different wards, and time of collection of urine samples, could not be ascertained while observing the trends. At the same time, ESBLs production was not detected by molecular biological methods, so there may be lower detection rates due to the influence of carbapenem production in the CR-KPN isolates on ESBLs detection.

## Conclusion

Taken together, our data demonstrated that there was a significant rise in the prevalence of carbapenem resistance and a decline in ESBL production in *K. pneumoniae* isolates from the patients with UTIs in our hospital. Further work and continuous surveillance are needed to advance the rational and judicious use of antimicrobial agents.

## Data Sharing Statement

The data sets used and analyzed during the current study are available from the corresponding author on reasonable request.

## Ethical Approval

The samples were part of the routine hospital laboratory procedure, not collected for this study, so an institutional review board will not be required.

## Acknowledgments

The authors would like to thank Xiaofei Xi (an English teacher in international Curriculum Centre of High School Affiliated to South West University, Chongqing, China) for the effort to make the language more accurate and more appropriate.

## Author Contributions

All authors read and approved the final manuscript. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

## Funding

This study was supported by the National Natural Science Foundation of China (Grant No. 82072349), and the

Medical Research Program of Chongqing Health and Family Planning Commission (No. 2018MSXM009).

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol*. 2015;13(5):269–284. doi:10.1038/nrmicro3432
2. Ikram R, Psutka R, Carter A, Priest P. An outbreak of multi-drug resistant *Escherichia coli* urinary tract infection in an elderly population: a case-control study of risk factors. *BMC Infect Dis*. 2015;15:224–230. doi:10.1186/s12879-015-0974-0
3. Sun JD, Huang SF, Yang SS, Pu SL, Zhang CM, Zhang LP. Impact of carbapenem heteroresistance among clinical isolates of invasive *Escherichia coli* in Chongqing, southwestern China. *Clin Microbiol Infect*. 2015;21(5):469.e1–e10. doi:10.1016/j.cmi.2014.12.013
4. Temkin E, Fallach N, Almagor J, et al. Estimating the number of infections caused by antibiotic-resistant *Escherichia coli* and *Klebsiella pneumoniae* in 2014: a modelling study. *Lancet Glob Health*. 2018;6(9):e969–e979. doi:10.1016/S2214-109X(18)30278-X
5. Pitout JDD, Nordmann P, Poirel L. Carbapenemase-producing *Klebsiella pneumoniae*, a key pathogen set for global nosocomial dominance. *Antimicrob Agents Chemother*. 2015;59(10):5873–5884. doi:10.1128/AAC.01019-15
6. Davarci I, Senbayrak S, Aksaray S, Kocoglu ME, Kuskucu MA, Samasti M. Molecular epidemiology of carbapenem-resistant *Klebsiella pneumoniae* isolates. *Anadolu Klinigi*. 2019;24(1):1–7. doi:10.21673/anadoluklin.423081
7. Koeijers JJ, Verbon A, Kessels AGH, et al. Urinary tract infection in male general practice patients: uropathogens and antibiotic susceptibility. *Urology*. 2010;76(2):336–340. doi:10.1016/j.urology.2010.02.052
8. Sokhn ES, Salami A, Roz AEI, Salloum L, Bahmad HF, Ghssein G. Antimicrobial susceptibilities and laboratory profiles of *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis* isolates as agents of urinary tract infection in Lebanon: paving the way for better diagnostics. *Med Sci (Basel)*. 2020;8(3):32–42.
9. Van Driel AA, Notermans DW, Meima A, et al. Antibiotic resistance of *Escherichia coli* isolated from uncomplicated UTI in general practice patients over a 10-year period. *Eur J Clin Microbiol Infect Dis*. 2019;38(11):2151–2158. doi:10.1007/s10096-019-03655-3
10. Ravi Shankar P, Balasubramaniam R. World Health Organization antimicrobial resistance: global report on surveillance 2014 (Book Review). *Australas Med J*. 2014;7(5):238–239.
11. Arnold RS, Thom KA, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ. Emergence of *Klebsiella pneumoniae* carbapenemase-producing bacteria. *South Med J*. 2011;104(1):40–45. doi:10.1097/SMJ.0b013e3181fd7d5a
12. Guh AY, Limbago BM, Kallen AJ. Epidemiology and prevention of carbapenem-resistant *Enterobacteriaceae* in the United States. *Expert Rev Anti Infect Ther*. 2014;12(5):565–580. doi:10.1586/14787210.2014.902306
13. Hu F-P, Guo Y, Zhu D-M, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. *Clin Microbiol Infect*. 2016;22(Suppl 1):S9–S14. doi:10.1016/j.cmi.2016.01.001
14. Cusack TP, Ashley EA, Ling CL, et al. Time to switch from CLSI to EUCAST? A Southeast Asian perspective. *Clin Microbiol Infect*. 2019;25(7):782–785. doi:10.1016/j.cmi.2019.03.016

15. Xu A, Zheng B, Xu Y-C, Huang Z-G, Zhong N-S, Zhuo C. National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013. *Clin Microbiol Infect*. 2016;22(Suppl 1):S1–S8. doi:10.1016/j.cmi.2015.09.015
16. VITEK®2 (AST-N334) [package insert]. Marcy l'Etoile, France: bioMérieux SA; 2018.
17. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing*. 29th ed. CLSI supplement M100. Wayne, PA: CLSI; 2019
18. Khan F, Siddiqui N, Sultan A, Rizvi M, Shukla I, Khan HM. Seasonal variation in *Klebsiella pneumoniae* blood stream infection: a five year study. *Clin Microbiol*. 2016;5(2):247. doi:10.4172/2327-5073.1000247
19. Xiao Y, Zhang J, Zheng B, Zhao L, Li S, Li L. Changes in Chinese policies to promote the rational use of antibiotics. *PLoS Med*. 2013;10(11):e1001556. doi:10.1371/journal.pmed.1001556
20. Wang X, Xu X, Li Z, et al. An outbreak of a nosocomial NDM-1-producing *Klebsiella pneumoniae* ST147 at a teaching hospital in Mainland China. *Microb Drug Resist*. 2014;20(2):144–149. doi:10.1089/mdr.2013.0100
21. Zhou J, Li G, Ma X, Yang Q, Yi J. Outbreak of colonization by carbapenemase-producing *Klebsiella pneumoniae* in a neonatal intensive care unit: investigation, control measures and assessment. *Am J Infect Control*. 2015;43(10):1122–1124. doi:10.1016/j.ajic.2015.05.038
22. Agodi A, Barchitta M, Quattrocchi A, et al. Antibiotic trends of *Klebsiella pneumoniae* and *Acinetobacter baumannii* resistance indicators in an intensive care unit of Southern Italy, 2008–2013. *Antimicrob Resist Infect Control*. 2015;4:43–49. doi:10.1186/s13756-015-0087-y
23. Federico MP, Furtado GH. Immediate and later impacts of antimicrobial consumption on carbapenem-resistant *Acinetobacter spp.*, *Pseudomonas aeruginosa*, and *Klebsiella spp.* in a teaching hospital in Brazil: a 10-year trend study. *Eur J Clin Microbiol Infect Dis*. 2018;37(11):2153–2158. doi:10.1007/s10096-018-3352-1
24. Candevir Ulu A, Kurtaran B, Inal AS, et al. Risk factors of carbapenem-resistant *Klebsiella pneumoniae* infection: a serious threat in ICUs. *Med Sci Monit*. 2015;21:219–224. doi:10.12659/MSM.892516
25. Qu X, Wang H, Chen C, et al. Surveillance of carbapenem-resistant *Klebsiella pneumoniae* in Chinese hospitals - a five-year retrospective study. *J Infect Dev Ctries*. 2019;13(12):1101–1107. doi:10.3855/jidc.11798
26. Jiang Y, Wei Z, Wang Y, Hua X, Feng Y, Yu Y. Tracking a hospital outbreak of KPC-producing ST11 *Klebsiella pneumoniae* with whole-genome sequencing. *Clin Microbiol Infect*. 2015;21(11):1001–1007. doi:10.1016/j.cmi.2015.07.001
27. Li H, Zhang J, Liu Y, et al. Molecular characteristics of carbapenemase-producing *Enterobacteriaceae* in China from 2008 to 2011: predominance of KPC-2 enzyme. *Diagn Microbiol Infect Dis*. 2014;78(1):63–65. doi:10.1016/j.diagmicrobio.2013.10.002
28. Qi Y, Wei Z, Ji S, Du X, Shen P, Yu Y. ST11, the dominant clone of KPC-producing *Klebsiella pneumoniae* in China. *J Antimicrob Chemother*. 2011;66(2):307–312. doi:10.1093/jac/dkq431
29. Zou C, Wei J, Shan B, Chen X, Wang D, Niu S. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against carbapenem-resistant *Enterobacteriaceae* isolates collected from three secondary hospitals in Southwest China Between 2018 and 2019. *Infect Drug Resist*. 2020;13:3563–3568. doi:10.2147/IDR.S273989
30. Wei J, Zou C, Wang D, Huang A, Niu S. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant *Enterobacteriaceae* isolates in Southwest China: a single-center study. *J Glob Antimicrob Resist*. 2020;22:448–451. doi:10.1016/j.jgar.2020.04.023
31. Deleo FR, Chen L, Porcella SF, et al. Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 *Klebsiella pneumoniae*. *Proc Natl Acad Sci U S A*. 2014;111(13):4988–4993. doi:10.1073/pnas.1321364111

## Infection and Drug Resistance

### Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

Dovepress